Weekly ReportOct 26 – Nov 1, 2026
Sepsis, week 44 edition
We read 297 papers and selected 3.
Summary
This week’s sepsis literature showed a strong shift toward biologically defined, mechanism-based care. Preclinical studies identified GSDMD palmitoylation, EZH2 lactylation, lactate-driven adipose browning, microbiota-dependent citrulline metabolism, and metabolic restoration of immunoparalysis as actionable pathways, while clinical cohorts advanced immune and clinical phenotyping. The most clinically actionable evidence supported adjunctive corticosteroids for septic shock and individualized restraint reduction, whereas studies of AI prediction, bedside flow-time monitoring, and rigid antibiotic-timing rules emphasized the limits of premature implementation. Overall, the field is moving toward precision sepsis medicine integrating immunometabolism, multimodal monitoring, standardized phenotypes, and implementation-focused stewardship.
Selected Articles
1. Nanocatalytic Inhibition of ROS-Dependent GSDMD Palmitoylation Mitigates Sepsis Progression.
This mechanistic study identified ROS-driven palmitoylation of GSDMD by ZDHHC5/ZDHHC9 as a previously unrecognized amplifier of canonical and non-canonical pyroptosis in sepsis. Vanadium oxide hydroxide nanosheets acted as catalytic ROS scavengers, inhibited GSDMD palmitoylation, reduced inflammatory tissue injury, and improved outcomes in two animal models. Human septic-cell observations and GSDMD-knockout experiments supported pathway specificity.
Impact: The paper identifies a chemically targetable regulatory step upstream of GSDMD-mediated pyroptosis and combines patient-derived evidence, nanomaterial optimization, multiple animal models, and genetic validation. It establishes a strong foundation for host-directed sepsis therapy, although clinical translation remains distant.
Clinical Implications: ROS-scavenging nanocatalysts or selective inhibitors of GSDMD palmitoylation could become adjunctive therapies, but pharmacokinetics, biodistribution, toxicity, effects on pathogen clearance, and therapeutic dosing must be established before human trials.
Key Findings
- GSDMD palmitoylation was increased in peripheral blood mononuclear cells from septic patients and was driven by ROS through ZDHHC5/ZDHHC9.
- Vanadium oxide hydroxide nanosheets inhibited canonical and non-canonical pyroptosis by scavenging ROS and suppressing GSDMD palmitoylation.
- The intervention reduced inflammatory injury and improved outcomes in two animal models, with GSDMD-knockout experiments supporting target specificity.
2. Immunological signatures of sepsis in abdominal solid organ transplant recipients: A multilayer and multicentric prospective cohort study.
In a post hoc analysis of a prospective multicenter cohort, abdominal solid organ transplant recipients with sepsis had higher 30-day survival than non-transplant patients, with survival of 84% versus 66% and an adjusted hazard ratio of 0.49. They showed lower IL-6 and TNF-alpha, higher IL-18, relatively preserved monocytic HLA-DR, and distinct innate immune, complement, lipid-metabolic, and cellular immunometabolic signatures. The findings suggest that chronic immunosuppression may reshape rather than simply suppress the septic host response.
Impact: The study challenges the assumption that chronic immunosuppression uniformly worsens sepsis outcomes and connects survival differences to measurable immune and immunometabolic mechanisms. Its multilayer profiling framework is highly relevant to individualized treatment of immunocompromised patients.
Clinical Implications: Transplant status should not automatically be interpreted as a marker of poor prognosis. Immune markers such as monocytic HLA-DR, cytokine patterns, and immunometabolic signatures may eventually guide individualized monitoring and immunomodulation, but they are not yet validated for routine treatment decisions.
Key Findings
- Thirty-day survival was 84% in abdominal solid organ transplant recipients versus 66% in non-transplant patients, with an adjusted hazard ratio of 0.49.
- Transplant recipients had lower IL-6 and TNF-alpha, higher IL-18, and relatively preserved monocytic HLA-DR expression.
- Proteomic and intracellular analyses identified distinct innate immune, complement, lipid-metabolic, and GLUT1/TFAM-associated signatures.
3. EZH2 lactylation: a key epigenetic regulator and potential therapeutic target for sepsis-associated lung injury.
Using 209 ICU patients, cecal ligation and puncture models, endothelial-specific Ezh2 knockout mice, pharmacologic interventions, and multi-omics, this study identified site-specific EZH2 K30/K406 lactylation as a lactate-responsive mechanism in sepsis-associated lung injury. EZH2 lactylation reduced EZH2 occupancy at the CITED2 promoter, enhanced NF-kappaB activity, and worsened pulmonary inflammation and endothelial dysfunction. Inhibiting lactate production or EZH2 lactylation improved lung injury in experimental models.
Impact: The paper links a clinically measurable metabolic abnormality, elevated lactate, to a specific post-translational epigenetic modification and a defined inflammatory transcriptional pathway. Human association, endothelial-specific genetics, and mechanistic intervention together make EZH2 lactylation a compelling therapeutic hypothesis.
Clinical Implications: Lactate kinetics may help identify patients with lactate-driven lung injury, while enzymes or molecular interfaces controlling EZH2 lactylation could become therapeutic targets. However, the patient component is observational and site-specific inhibitors have not been clinically tested.
Key Findings
- Serum lactate was elevated in patients with sepsis-associated lung injury and was associated with inflammatory markers and injury severity.
- EZH2 K30/K406 lactylation increased with disease progression and reduced EZH2 occupancy at the CITED2 promoter.
- Inhibiting lactate production or EZH2 lactylation improved pulmonary function and reduced inflammation, pathological injury, and endothelial dysfunction.